Global Immuno-oncology Market Report 2020: I-O Market is Expected to Reach $132.66 Billion by 2025, Growing at a Rate of 11.6% and Witness Minimal Impact From COVID-19

News provided by

Mar 01, 2021, 11:00 ET

DUBLIN, March 1, 2021 /PRNewswire/ -- The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering.

This study explores the global immuno-oncology (I-O) market's evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by the analyst to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions.

The study considers oncology agents for which the immune system is the basis of their actions, including monoclonal antibodies, cell and gene therapies, bioengineered vaccines, recombinant products, small molecules, and oncolytic viruses. Classified into 5 major therapy types - immunomodulators, adoptive cell therapy, cancer vaccine, oncolytic virus, and antibody-based targeted therapies - the analysis provides revenue forecasts by the global market and product category. The agents are classified into various therapy types based on the mechanism of action (MOA). Concerning pipeline products, we have considered industry-sponsored products under development.

The oncology therapeutic segment is expected to witness minimal impact from the COVID-19 pandemic because of the criticality of treating cancer patients and the segment's role as a major revenue-generator for pharmaceutical companies. The analyst have considered the impact of COVID-19 and two scenarios for the sales forecast: original scenario and COVID-19 impact scenario.

In the original scenario, the I-O market is expected to reach $132.66 billion by 2025 growing at a rate of 11.6% and witness minimal impact from the COVID-19 pandemic, with 2020 accounting for the majority of the decline. After 2022, the market will positively recuperate and experience a slight increase in revenue due to rebounding R&D budgets and accelerated developments of late-stage clinical candidates.

Research Highlights

Major Themes Covered in This Study:

Strategic imperatives and key findings
Overview of I-O market, including the journey from bench to bedside, the value chain and stakeholder ecosystem, R&D expenditure, funding, and investment
Clinical trial overview for all therapies in consideration, with details for each I-O target and agent
Regulatory and reimbursement scenario, including risk-sharing models
Key marketed and pipeline products, market and technology dashboard
Extensive growth opportunity analysis with metrics, drivers, restraints, and competitive environment
Market revenue forecast and share analysis for each product segment
Calls to action aligned with the recommended growth opportunities
Key company profiles

Key Topics Covered:

1. Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative
The Impact of the Top Three Strategic Imperatives on the Immuno-oncology (I-O) Industry
Growth Opportunities Fuel the Growth Pipeline Engine

2. Executive Summary

Key Findings for the Immuno-oncology Market-Rising Incidences of Cancer, R&D Portfolio Management, and Regulatory Pathways
Key Findings for the Immuno-oncology Market-Breakthrough Innovations, Program Acceleration, and Smart Production
Market Snapshot, Global Immuno-oncology Market
Summary of Growth Opportunities-Best Suited Therapy Design
Summary of Growth Opportunities-Optimal Path to Market

3. Market Overview-Immuno-oncology

Characteristics of Immuno-oncology Therapies-Journey from Bench to Bedside

4. Immuno-oncology Value Chain and R&D Expenditure-Immuno-oncology

Immuno-oncology Clinical Development Process and Approach
Immuno-oncology Value Chain and Stakeholder Ecosystem
Immuno-oncology from Early Stages to Product Launch
Immuno-oncology R&D Funding and Investment

5. Clinical Trial Overview-Immuno-oncology

Clinical Trials Snapshot for Immuno-oncology Therapies
Clinical Trials Snapshot for T-cell Targeting Immunomodulators
Clinical Trials Snapshot for Other Immunomodulators
Clinical Trials Snapshot for Adoptive Cell Therapies
Clinical Trials Snapshot for Targeted Cell Types
Clinical Trials Snapshot for Cancer Vaccines
Clinical Trials Snapshot for Oncolytic Viral Therapies
Clinical Trials Snapshot for Bispecific Antibodies (BsAbs)
Clinical Trials Snapshot for Immuno-oncology Agents
Clinical Trials Snapshot for Immuno-oncology Treatments

6. Regulatory and Reimbursement Scenario-Immuno-oncology

Regulatory Framework for Immuno-oncology Therapy Approval
Regulatory Approaches to Advance Immuno-oncology Therapies
Reimbursement Scenario across the Immuno-oncology Space
Risk Sharing Model for Immuno-oncology Therapies

7. Key Marketed and Pipeline Products Dashboard-Immuno-oncology

Marketed Product Dashboard-Checkpoint InhibitorsOpdivo (nivolumab): Bristol-Myers Squibb
Marketed Product Dashboard-Checkpoint InhibitorsKeytruda (pembrolizumab): Merck & Co
Marketed Product Dashboard-Checkpoint InhibitorsYervoy (ipilimumab): Bristol-Myers Squibb
Marketed Product Dashboard-Checkpoint InhibitorsTecentriq (atezolizumab): Roche/Genentech
Marketed Product Dashboard-Checkpoint InhibitorsImfinzi (durvalumab): AstraZeneca
Marketed Product Dashboard-Adoptive Cell TherapyYescarta (KTE-C19, axicabtagene ciloleucel): Kite Pharma-Gilead
Marketed Product Dashboard-Adoptive Cell TherapyKymriah (CTL019, tisagenlecleucel): Novartis
Marketed Product Dashboard-Bispecific AntibodiesBLINCYTO (blinatumomab): Amgen
Pipeline Product Dashboard-ImmunomodulatorBempegaldesleukin (NKTR-214): Nektar Therapeutics
Pipeline Product Dashboard-ImmunomodulatorTilsotolimod (IMO-2125): Idera Pharmaceuticals
Pipeline Product Dashboard-Checkpoint InhibitorMagrolimab (GS-4721): Gilead Sciences/Forty Seven
Pipeline Product Dashboard-ImmunomodulatorDostarlimab (TSR-042, WBP-285): GlaxoSmithKline
Pipeline Product Dashboard-Adoptive Cell TherapyLisocabtagene Maraleucel (liso-cel): Bristol-Myers Squibb
Pipeline Product Dashboard-Adoptive Cell TherapyIdecabtagene Vicleucel (ide-cel, bb2121): Bristol-Myers Squibb
Pipeline Product Dashboard-Checkpoint InhibitorTislelizumab (BGB-A317): BeiGene
Pipeline Product Dashboard-Checkpoint InhibitorCamrelizumab (AiRuiKaT, SHR-1210): Jiangsu HengRui Medicine
Companies to Watch in the Immuno-oncology Space-Robust Biotech Platforms
Companies to Watch in the Immuno-oncology Space-Flexible Bioengineering Solutions

8. Growth Opportunity Analysis-Global Immuno-oncology Market

Global Immuno-oncology Market Scope of Analysis
Global Immuno-oncology Market Segmentation
Key Growth Metrics for Immuno-oncology Market
Growth Drivers for Immuno-oncology Market
Growth Restraints for Immuno-oncology Market
Forecast Assumptions-Global Immuno-oncology Market
Forecast Assumptions-Global Immuno-oncology Market (continued)
Revenue Forecast-Global Immuno-oncology Market
Revenue Forecast by Product-Global Immuno-oncology Market
Revenue Forecast Analysis-Global Immuno-oncology Market
Competitive Environment-Global Immuno-oncology Market
Revenue Share-Global Immuno-oncology Market
Revenue Share Analysis-Global Immuno-oncology Market

9. Growth Opportunity Analysis-Immunomodulators

Key Growth Metrics for Immunomodulators
Revenue Forecast-Immunomodulators
Forecast Analysis-Immunomodulators
Approved Immune Checkpoint Inhibitors as I-O Therapies
Approved Immunomodulators as I-O Therapies

10. Growth Opportunity Analysis-Adoptive Cell Therapy

Key Growth Metrics for Adoptive Cell Therapy
Revenue Forecast-Adoptive Cell Therapy
Forecast Analysis-Adoptive Cell Therapy
Autologous vs Allogeneic Adoptive Cell Therapy Challenges
Approved Adoptive Cell Therapies as I-O Therapies

11. Growth Opportunity Analysis-Antibody-based Targeted Therapies

Key Growth Metrics for Antibody-based Targeted Therapies
Revenue Forecast-Antibody-based Targeted Therapies
Forecast Analysis-Antibody-based Targeted Therapies
Approved Targeted Monoclonal Antibodies as I-O Therapies
Approved Antibody Drug Conjugates as I-O Therapies

12. Growth Opportunity Analysis-Cancer Vaccine and Oncolytic Virus

Key Growth Metrics for Cancer Vaccine and Oncolytic Virus
Revenue Forecast-Cancer Vaccine and Oncolytic Virus
Forecast Analysis-Cancer Vaccine and Oncolytic Virus
Approved Cancer Vaccines as I-O Therapies
Approved Oncolytic Virus as I-O Therapies

13. Growth Opportunity Universe-Immuno-oncology

Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020
Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Call to Action
Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combinations
Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combination Cases
Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combination Cases (continued)
Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020
Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Call to Action
Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Business Model
Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Smart Facilities
Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Smart Cell Cases
Growth Opportunity 3: Novel Engineering Platforms for Support Precision Oncology, 2020
Growth Opportunity 3: Novel Engineering Platforms for Supporting Precision Oncology, 2020-Call to Action
Growth Opportunity 3: Novel Engineering Platforms for Support Precision Oncology, 2020-Biotech Platforms
Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020
Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Call to Action
Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Strategies
Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020- Biomarkers
Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Relevant Cases
Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Relevant Cases (continued)
Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020
Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Call to Action
Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-New Approaches
Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Improved Measures
Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Tele-oncology Landscape
Growth Opportunity 6: Asia-Pacific in the Spotlight for Accelerating I-O Programs, 2020
Growth Opportunity 6: Asia-Pacific in the Spotlight for Accelerating I-O Programs, 2020-Call to Action

14. Key Company Profiles-Immuno-oncology

Key Global Competitors for Immuno-oncology-Amgen Dashboard
Key Global Competitors for Immuno-oncology-Amgen Focus
Key Global Competitors for Immuno-oncology-AstraZeneca Dashboard
Key Global Competitors for Immuno-oncology-AstraZeneca Focus
Key Global Competitors for Immuno-oncology-Bristol-Myers Squibb Dashboard
Key Global Competitors for Immuno-oncology-Bristol-Myers SquibbFocus
Key Global Competitors for Immuno-oncology-Daiichi Sankyo Dashboard
Key Global Competitors for Immuno-oncology-Daiichi Sankyo Focus
Key Global Competitors for Immuno-oncology-Eli Lilly Dashboard
Key Global Competitors for Immuno-oncology-Eli Lilly Focus
Key Global Competitors for Immuno-oncology-Johnson & Johnson Dashboard
Key Global Competitors for Immuno-oncology-Johnson & Johnson Focus
Key Global Competitors for Immuno-oncology-Merck & Co Dashboard
Key Global Competitors for Immuno-oncology-Merck & Co Focus
Key Global Competitors for Immuno-oncology-Novartis Dashboard
Key Global Competitors for Immuno-oncology-Novartis Focus
Key Global Competitors for Immuno-oncology-Pfizer Dashboard
Key Global Competitors for Immuno-oncology-Pfizer Focus
Key Global Competitors for Immuno-oncology-Roche Dashboard
Key Global Competitors for Immuno-oncology-Roche Focus

15. Next Steps

For more information about this report visit https://www.researchandmarkets.com/r/xmzjtj

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets